Derivatives of cyclopamine that target SMO, such as vismodegib (GDC-0449), as well as other SMO inhibitors such as sonidegib (LDE-225), are currently in clinical trials for patients with BCC and medulloblastoma24, 25. Here, SMO is linked to skin basal cell carcinoma.